These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17575158)

  • 21. Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer.
    Lau D; Guo L; Liu R; Marik J; Lam K
    Lung Cancer; 2006 Jun; 52(3):291-7. PubMed ID: 16635537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
    Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
    Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis.
    John AE; Luckett JC; Tatler AL; Awais RO; Desai A; Habgood A; Ludbrook S; Blanchard AD; Perkins AC; Jenkins RG; Marshall JF
    J Nucl Med; 2013 Dec; 54(12):2146-52. PubMed ID: 24167080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical and pathological significance of RCAS1 expression as a prognostic biomarker in non-small cell lung cancer.
    Tsoukalas N; Kostakis ID; Siakavellas S; Giaginis C; Bournakis E; Sfiniadakis I; Karameris A; Patsouris E; Theocharis S
    In Vivo; 2014; 28(3):375-81. PubMed ID: 24815841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
    Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different biomarkers in non-small cell lung cancer in blood vessel invasion.
    Zhang C; Liu Y; Guo S; Zhang J
    Cell Biochem Biophys; 2014 Nov; 70(2):777-84. PubMed ID: 24801771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and evaluation of a radioiodinated peptide probe targeting αvβ6 integrin for the detection of pancreatic ductal adenocarcinoma.
    Ueda M; Fukushima T; Ogawa K; Kimura H; Ono M; Yamaguchi T; Ikehara Y; Saji H
    Biochem Biophys Res Commun; 2014 Mar; 445(3):661-6. PubMed ID: 24583127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6.
    Ramsay AG; Keppler MD; Jazayeri M; Thomas GJ; Parsons M; Violette S; Weinreb P; Hart IR; Marshall JF
    Cancer Res; 2007 Jun; 67(11):5275-84. PubMed ID: 17545607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library.
    Zang L; Shi L; Guo J; Pan Q; Wu W; Pan X; Wang J
    Cancer Lett; 2009 Aug; 281(1):64-70. PubMed ID: 19327883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2.
    Slack RJ; Hafeji M; Rogers R; Ludbrook SB; Marshall JF; Flint DJ; Pyne S; Denyer JC
    Pharmacology; 2016; 97(3-4):114-25. PubMed ID: 26734728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting.
    Cardle II; Jensen MC; Pun SH; Sellers DL
    J Biol Chem; 2021; 296():100657. PubMed ID: 33857478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinoic acid receptor-beta expression in stage I non-small cell lung cancer and adjacent normal appearing bronchial epithelium.
    Chang YS; Chung JH; Shin DH; Chung KY; Kim YS; Chang J; Kim SK; Kim SK
    Yonsei Med J; 2004 Jun; 45(3):435-42. PubMed ID: 15227730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profiling of integrins in lung cancer cells.
    Guo L; Zhang F; Cai Y; Liu T
    Pathol Res Pract; 2009; 205(12):847-53. PubMed ID: 19674850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas.
    McGuire MJ; Samli KN; Chang YC; Brown KC
    Exp Hematol; 2006 Apr; 34(4):443-52. PubMed ID: 16569591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
    Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
    Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
    Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.